Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for De Novo Acute Myelogenous Leukemia with a Conditioning Regimen of Total Body Irradiation and Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 6, 2008, Pages 651-657

  Mori, Takehiko ^a   Aisa, Yoshinobu ^a   Watanabe, Reiko ^b   Yamazaki, Rie ^a   Kato, Jun ^a   Shimizu, Takayuki ^a   Shigematsu, Naoyuki ^a   Kubo, Atsushi ^a   Yajima, Tomonaru ^a   Hibi, Toshifumi ^a   Ikeda, Yasuo ^a   Okamoto, Shinichiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL CENTER   (Japan)

Author keywords

Acute myelogenous leukemia; Allogeneic hematopoietic stem cell transplantation; Granulocyte colony stimulating factor; High dose cytarabine

Indexed keywords

CYCLOSPORIN A; CYTARABINE; HLA ANTIGEN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DISEASE FREE SURVIVAL; DONOR; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KERATITIS; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; RADIATION DOSE; RETROSPECTIVE STUDY; SIBLING; STOMATITIS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 43449112656     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.03.006     Document Type: Article

References (34)

1. Ringdén O., Horowitz M.M., Sondel P., et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood 81 (1993) 1094-1101
2. Zittoun R.A., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332 (1995) 217-223
3. Gale R.P., Buchner T., Zhang M.-J., et al. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia 10 (1996) 1687-1691
4. Mehta J., Powles R., Treleaven J., et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 18 (1996) 741-746
5. Litzow M.R., Pérez W.S., Klein J.P., et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 119 (2002) 1115-1124
6. Frassoni F., Labopin M., Gluckman E., et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 8 (1994) 924-928
7. Copelan E.A., Biggs J.C., Thompson J.M., et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 78 (1991) 838-843
8. Michallet M., Thomas X., Vernant J.P., et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant 26 (2000) 1157-1163
9. Biggs J.C., Horowitz M.M., Gale R.P., et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80 (1992) 1090-1093
10. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 10 (1992) 1723-1729
11. Fung H.C., Stein A., Slovak M.L., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 9 (2003) 766-771
12. Miyauchi J., Kelleher C.A., Wang C., Minkin S., and McCuloch E.A. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 73 (1989) 1272-1278
13. Waga K., Furusawa S., Nagashima S., Saito K., and Shishido H. Comparative effects of G-CSF, GM-CSF, and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors. Int J Hematol 56 (1992) 17-27
14. Takahashi S., Okamoto S.-I., Shirafuji N., et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant 13 (1994) 239-245
15. Tafuri A., De Felice L., Petrucci M.T., et al. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen. Cytokine Mol Ther 1 (1995) 301-307
16. Estey F., Thall P., Andreeff M., et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12 (1994) 671-678
17. Saito K., Nakamura Y., Aoyagi M., et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess of blasts in transformation. Int J Hematol 71 (2000) 238-244
18. Lowenberg B., van Putten W., Theobald M., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349 (2003) 743-752
19. Amadori S., Suciu S., Jehn U., et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 106 (2005) 27-34
20. Okamoto S., Takahashi S., Wakui M., et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. Br J Haematol 104 (1999) 569-573
21. Takahashi S., Oshima Y., Okamoto S.-I., et al. Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. Am J Hematol 57 (1998) 303-308
22. Takahashi S., Iseki T., Ooi J., et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104 (2004) 3813-3820
23. Mori T., Aisa Y., Yokoyama A., et al. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Bone Marrow Transplant 39 (2007) 217-221
24. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 (2004) 961-968
25. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
26. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
27. Przepiorka D., Weisdorf D., Martin P., et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
28. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
29. Riddell S., Appelbaum F.R., Buckner C.D., et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 6 (1988) 576-582
30. Kamani N., Bayever E., August C.S., Bunin N., Goldwein J.W., and D'Angio G.J. Fractionated toral-body irradiation preceding high-dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia. Med Pediatr Oncol 25 (1995) 179-184
31. Imamura M., Asano S., Harada M., et al. Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. Int J Hematol 83 (2006) 164-178
32. Ferrant A., Labopin M., Frassoni F., et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 90 (1997) 2931-2938
33. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102 (2003) 1232-1240
34. Gale R.P., Horowitz M.M., Weiner R.S., et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 16 (1995) 203-208